Intra-Cellular Therapies (ITCI) Reports Q1 Loss of $0.63/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 8, 2019 7:35 AM EDTNEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2019, and provided a corporate update.
2018 was an important year for ITCI and our momentum has carried over into 2019, said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. Our NDA for lumateperone for the treatment of schizophrenia is under review and we continue to make progress in preparing all areas of the Company for the potential launch... More
